As healthcare continues to prioritize early detection and effective disease management, the Infectious Disease In Vitro Diagnostics Market is becoming increasingly significant. Developments in laboratory testing, molecular technologies, and diagnostic workflows are helping strengthen the ability of healthcare systems to identify infectious diseases.

According to The Insight Partners, the infectious disease in vitro diagnostics market is expanding due to the growing global burden of diseases such as HIV, tuberculosis, hepatitis, malaria, COVID-19, and other emerging infections. The market analysis highlights the increasing importance of rapid and precise diagnostic solutions. Advances in PCR, nucleic acid amplification testing, next-generation sequencing, microfluidics, immunoassays, and AI-enabled platforms are supporting faster and more accurate infectious disease detection. Point-of-care and home testing are also gaining importance as healthcare providers and consumers seek convenient diagnostic solutions.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00040978

Infectious Disease In Vitro Diagnostics Market Size and Share

The infectious disease in vitro diagnostics market size was valued at 45.69 billion in 2024 and is projected to reach 76.71 billion by 2031. The market is expected to register a CAGR of 7.7% during 2025–2031. The report identifies North America as the leading regional market, accounting for 41.8% of the market share in 2024. Asia Pacific is projected to register a CAGR of 8.6% during the forecast period, while the United States market is expected to grow at a CAGR of 7.4%. These regional developments reflect increasing adoption of technologically advanced diagnostic products, research and development activities, disease surveillance, and demand for infectious disease testing.

Infectious Disease In Vitro Diagnostics Market Drivers

The increasing prevalence of infectious diseases is a major factor supporting infectious disease in vitro diagnostics market growth. The report highlights the continued burden of tuberculosis, HIV, fungal infections, hepatitis, influenza, and emerging viral infections. The need for early detection and appropriate treatment is increasing demand for rapid and precise diagnostic solutions. Technological innovation is another important growth driver, with molecular diagnostics, PCR, NAAT, NGS, advanced immunoassays, lab-on-a-chip systems, and point-of-care devices improving diagnostic capabilities.

Government initiatives focused on disease awareness, early detection, screening, and disease management are also creating opportunities for the market. Public health programs addressing tuberculosis, HIV, hepatitis, malaria, and dengue incorporate screening activities that support demand for centralized and point-of-care diagnostic platforms. Government-backed research and development programs, regulatory support, public-private collaborations, and investments in disease surveillance are further supporting diagnostic innovation.

Infectious Disease In Vitro Diagnostics Market Segmentation

The infectious disease in vitro diagnostics market is segmented based on application and end user. By application, the market is categorized into HIV or AIDS, tuberculosis, hepatitis B and C, malaria, and others. The hepatitis B and C segment accounted for the largest market share in 2024, representing 30.4% of the market. The continued requirement for accurate infectious disease detection supports the use of in vitro diagnostic technologies across these application areas.

By end user, the market is segmented into hospitals and clinics, diagnostic laboratories, blood banks, and others. Hospitals and clinics dominated the market in 2024, while diagnostic laboratories are anticipated to register the fastest growth, with a CAGR of 8.3% during the forecast period. The report also covers five major geographical regions: North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa.

Top Key Players

The infectious disease in vitro diagnostics market includes several established diagnostic and healthcare companies. Key players profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Becton Dickinson and Co., Sysmex Corp., bioMerieux SA, Bio-Rad Laboratories Inc., QIAGEN NV, QuidelOrtho Corp., and Bruker Corp. The report evaluates these companies within the competitive landscape while examining developments in products, technologies, services, and other market activities.

Infectious Disease In Vitro Diagnostics Market Growth and Opportunities

The infectious disease in vitro diagnostics market presents opportunities through continued technological innovation, increasing disease surveillance, and expanding awareness of early diagnosis. Government-supported screening initiatives and investments in healthcare infrastructure are creating additional opportunities for diagnostic companies. The expansion of point-of-care testing and home diagnostics, combined with advances in molecular testing and AI-enabled diagnostic platforms, is also supporting market development.

North America held a significant market share in 2024 due to the acceptance of advanced technologies, strong research and development activities, use of infectious disease diagnostic kits, and the presence of major healthcare businesses. Asia Pacific is expected to record a faster growth rate during the forecast period, supported by the increasing demand for infectious disease diagnostics and healthcare development.

Future Outlook

The future outlook for the infectious disease in vitro diagnostics market remains centered on technological advancement, early disease detection, and expanding diagnostic access. The market is projected to grow from 45.69 billion in 2024 to 76.71 billion by 2031 at a CAGR of 7.7% during 2025–2031. Continued innovation in PCR, NAAT, NGS, immunoassays, point-of-care systems, microfluidics, automation, and AI-supported diagnostics is expected to shape market development.

The increasing global burden of infectious diseases and continued investments in disease preparedness and surveillance are expected to sustain demand for diagnostic solutions. As healthcare providers increasingly focus on faster and more accurate detection, infectious disease in vitro diagnostics are expected to remain an important component of infectious disease management and healthcare testing through 2031.

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:
Contact Person: Ankit Mathur 
E-mail: [email protected]
Phone: +1-646-491-9876